Results 61 to 70 of about 40,241 (253)
British Journal of Clinical Pharmacology, EarlyView.Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman +5 more
wiley +1 more source
Limited Options to Manage Specialty Drug Spending [PDF]
, 2012 Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core
Regulatory Science Ireland: bridging the information gap on biosimilar medicines [PDF]
, 2016 Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government agencies.
Barry, Sean P. +6 more
core +1 more source
PLoS ONE, 2022 Healthcare systems have reached a critical point regarding the question of whether biosimilar substitution should become common practice. To move the discussion forward, the study objective was to investigate the views of experts from medicines agencies ...
L. Druedahl +6 more
semanticscholar +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source
Manufacturing Barriers to Biologics Competition and Innovation [PDF]
, 2016 As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely
Price, W. Nicholson, II, Rai, Arti K.
core +2 more sources
Biotechnology and Bioengineering, EarlyView.ABSTRACT The competition in the biopharmaceutical market is increasing due to the market entry of biosimilars and rising costs in research and development of new drugs. Hence, continuous manufacturing gained significant attention due to its potential in reducing production cycle times and costs, as well as the possibility of real‐time release testing ...
Mariana Carvalho +4 more
wiley +1 more source
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
BioDrugs, 2022 Background Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases.
Saana V. Luukkanen +3 more
semanticscholar +1 more source
Biotechnology and Bioengineering, EarlyView.Schematic representation of the continuous lab‐scale process. ABSTRACT Monoclonal antibodies (mAbs) are nowadays fundamental in treating a wide range of severe diseases, including cancer, infections, or autoimmune disorders. Due to their high specificity, potent activity, and fewer side effects compared to small molecular drugs, the market for mAbs is ...
Thomas Kruse +5 more
wiley +1 more source
What NMR can do in the biopharmaceutical industry [PDF]
, 2018 LBK
Fizil, Ádám +2 more
core +1 more source